|Medical therapy of bone metastases of breast cancer

doi:10.3760/cma.j.issn.1673-422X.2015.12.010

Abstract

Abstract: Approximately 70% advanced breast cancer will develop bone metastases. Bone metastases can cause a series of complications such as skeletalrelated events, seriously affecting the quality of life of the patients. Therefore, it is very important to choose the reasonable and effective treatments. Bisphosphonates are the standard treatments of bone metastatic breast cancer, denosumab may also be a reasonable alternative to bisphosphonates in the near future, while chemotherapy, endocrinotherapy and targeted therapy are the basic treatments of advanced breast cancer, combined use of various treatments will get the best efficacy.

Key words: Breast neoplasms, Neoplasm metastasis, Therapy, Skeletal-related event

Xie Xiaojuan, Tong Zhongsheng. |Medical therapy of bone metastases of breast cancer[J]. Journal of International Oncology, 2015, 42(12): 920-923.

References

［1］张思嘉，马迪，何仲．肥胖与乳腺癌关系的研究进展［J］．肿瘤防治研究， 2012， 39（10）： 1265-1268．［2］ Rucci N, Sanità P, Delle Monache S, et al. Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets［J］. World J Clin Oncol, 2014, 5(3): 335-347. ［3］ Wang X, Yang KH, Wanyan P, et al. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A metaanalysis of randomized controlled trials［J］. Oncol Lett, 2014, 7(6): 1997-2002. ［4］ Harries M, Taylor A, Holmberg L, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients［J］. Cancer Epidemiol, 2014, 38(4): 427-434. ［5］ Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer［J］. Lancet Oncol, 2009, 10(6): 615-621. ［6］孙姗姗，张月蒙，高英杰，等．骨改良药治疗骨转移的研究进展［J］．国际肿瘤学杂志， 2014， 41（3）： 226-228．［7］ Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review)［J］. Oncol Lett, 2013, 6(2): 306-310. ［8］董梅，陈学鹏，冯奉仪．双膦酸盐治疗恶性肿瘤骨转移的研究进展［J］．中华肿瘤杂志， 2007， 32（11）： 801-803．［9］ Mathew A, Brufsky A. Bisphosphonates in breast cancer［J］. Int J Cancer, 2015, 137(4): 753-764. ［10］ Keizman D, IshShalom M, Pili R, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma［J］. Eur J Cancer, 2012, 48(7): 1031-1037. ［11］胡洁芬，陈懿，吴文．双膦酸盐的发展及临床应用［J］．中华关节外科杂志:电子版， 2013， 7（2）： 265-268．［12］ Paterson AH, Powles TJ, Kanis JA, et al. Doubleblind controlled trial of oral clodronate in patients with bone metastases from breast cancer［J］. J Clin Oncol, 1993, 11(1): 59-65. ［13］ Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term followup of two randomized, placebocontrolled trials［J］. Cancer, 2000, 88(5): 1082-1090. ［14］ Hortobagyi GN, Theriault RL, Lipton A, et al. Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group［J］. J Clin Oncol, 1998, 16(6): 2038-2044. ［15］ Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebocontrolled trial. Protocol 18 Aredia Breast Cancer Study Group［J］. J Clin Oncol, 1999, 17(3): 846-854. ［16］ Rosen LS, Gordon D, Kaminski M, et al. Longterm efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial［J］. Cancer, 2003, 98(8): 1735-1744. ［17］ Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion［J］. Cancer, 2004, 100(1): 36-43. ［18］ Amadori D, Aglietta M, Alessi B, et al. Efficacy and safety of 12weekly versus 4weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, openlabel, randomised, noninferiority trial［J］. Lancet Oncol, 2013, 14(7): 663-670. ［19］ Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases［J］. Ann Oncol, 2003, 14(9): 1399-1405. ［20］ Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebocontrolled phase Ⅲ studies［J］. Br J Cancer, 2004, 90(6): 1133-1137. ［21］ BarrettLee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, noninferiority phase 3 trial［J］. Lancet Oncol, 2014, 15(1): 114-122. ［22］中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2013版)［J］．中国癌症杂志， 2013（8）： 637-693．［23］ Ding X, Fan Y, Ma F, et al. Prolonged administration of bisphosphonates is welltolerated and effective for skeletalrelated events in Chinese breast cancer patients with bone metastasis［J］. Breast, 2012, 21(4): 544-549. ［24］ Kumar V, Shahi AK. Nitrogen containing bisphosphonates associated osteonecrosis of the Jaws: A review for past 10 year literature［J］. Dent Res J (Isfahan), 2014, 11(2): 147-153. ［25］ Boyce BF, Xing LP. Biology of RANK, RANKL, and osteoprotegerin［J］. Arthritis Res Ther, 2007, 9(Suppl 1): S1. ［26］许宋锋， Adams B, 于秀淳，等．骨巨细胞瘤治疗新突破——狄诺塞麦［J］．国际骨科学杂志， 2013， 34（6）： 387-392．［27］乔光磊，郑水儿，祁伟祥，等．狄诺塞麦与唑来膦酸治疗恶性实体瘤骨转移和多发性骨髓瘤骨相关事件的疗效和安全性的比较: 一项Meta分析［J］．肿瘤， 2013， 33（1）： 48-57．［28］ Barton MK. Denosumab an option for patients with bone metastasis from breast cancer［J］. CA Cancer J Clin, 2011, 61(3): 135-136. ［29］ Smith MR, Saad F, Coleman R, et al. Denosumab and bonemetastasisfree survival in men with castrationresistant prostate cancer: results of a phase 3, randomised, placebocontrolled trial［J］. Lancet, 2012, 379(9810): 39-46. ［30］ Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011［J］. Ann Oncol, 2011, 22(8): 1736-1747. ［31］黄曼，郭保凤，吴金娜，等．靶向治疗乳腺癌骨转移的研究进展［J］．现代生物医学进展， 2013， 13（1）： 184-186, 111．

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.